In this episode of Denatured, you’ll listen to Ram May-Ron, managing partner at FreeMind Group, and Ravi Kiron, managing director at Biopharma Strategy Advisors. We’ll be speaking about how to combine nondilutive funding and family office money into a unified strategy that gets companies through the drug development valley of death.
> Listen on Spotify
> Listen on Apple Podcasts
> Listen on Amazon Music
> Listen on iHeart
In this Denatured episode, Jennifer C. Smith-Parker speaks to Ram May-Ron, managing partner at FreeMind Group, and Ravi Kiron, managing director at Biopharma Strategy Advisors. We’ll discuss how best to tailor an investment approach of both nondilutive funding and family offices to overcome the drug development valley of death.
Host
Jennifer Smith-Parker, Director of Insights, BioSpace
Guests
Ram May-Ron, Managing Partner, FreeMind Group
Ravi Kiron, Managing Director, Biopharma Strategy Advisors
Disclaimer: The views expressed in this discussion by guests are their own and do not represent those of their organizations.
